PATENT CLAIM ANALYSIS

Application Number: 16244161
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["514", "249000"]

Abstract:
The present invention relates to certain SGLT-2 inhibitors, such as ertugliflozin or a co-crystal or a pharmaceutically acceptable salt thereof, for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD). The present invention also relates to methods for preventing neuronal damage following the incidence of ischemic stroke and close-head traumatic brain injury in animals comprising the step of administering to an animal, in need of such treatment, a therapeutically effective amount of ertugliflozin or a co-crystal or a pharmaceutically acceptable salt thereof

Claim (Index 15):
The method of  claim 14  comprising determining that the eGFR of a patient in need of treatment for prediabetes, type 1 or type 2 diabetes is between \u226545 ml/min/1.73 m 2  and <60 ml/min/1.73 m 2 .

Metadata:
- Claim Count in Document: 47.0
- Percentile: 99.0
- Lexical Diversity: 1.56522
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15523512', '12546306', '15576452', '14435730', '13813045']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7993241453113927
- 35 USC 102 Novelty (BERT): 0.5745314667152942
- Combined Prediction Score: 0.7768448774517829
- Mean Citation Score: 335.72153
- Max Citation Score: 543.8519
- Similarity Product: 352.65675419079065

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test